Accessibility Menu
Santen Pharmaceutical logo

Santen Pharmaceutical(OTC) SNPHF

Market Cap$4.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-16%
5 Year+9%
1 Year+17%
1 Month+0%
$13.05
+4.40%
+0.55Today
Santen Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 13.052026-08-11
Santen Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 13.052026-07-13
1 month+0%USD 13.052026-06-30
3 month+20.05%USD 10.872026-03-13
Year to date+38.76%USD 9.402025-11-25
1 year+16.53%USD 11.202025-06-27
3 year+51.8%USD 8.602023-08-10
5 year+8.94%USD 11.982021-08-06
Since inception-15.82%USD 15.502004-05-04

Santen Pharmaceutical Financials at a Glance

Market Cap

$4.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥292.91B

Net Income (TTM)

¥38.84B

EPS (TTM)

$0.77

P/E Ratio

16.88

Dividend

$0.25

Beta (Volatility)

0.06 (Low)

Price

$13.05

Volume

7

Open

$13.06

Previous Close

$13.05

Daily Range

$13.05 - $13.06

52-Week Range

$8.88 - $13.06

Estimated Earnings Date

Nov 5, 2026

SNPHF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. is a global leader in the research, development, manufacturing, and commercialization of pharmaceuticals and medical devices, with a strong emphasis on ophthalmology. Headquartered in Osaka, Japan, the company is dedicated to addressing various eye conditions through innovative treatments and a robust product pipeline.

Products and Services
  • Specializes in ophthalmic pharmaceuticals for conditions like glaucoma and ocular hypertension
  • Offers over-the-counter (OTC) pharmaceutical products
  • Develops treatments for myopia and dry eye conditions
Growth Outlook
  • Pipeline includes multiple Phase III clinical trials for glaucoma treatments
  • Expansion into new markets with ongoing trials in the U.S. and Europe
  • Strong focus on R&D to enhance product offerings and market reach
Financial Highlights
  • Recent quarterly revenue of 81.37 billion JPY, reflecting a significant increase
  • Trailing twelve months (TTM) net income margin of 12.81%, indicating profitability
  • Current ratio of 2.60, showcasing strong liquidity position
Santen Pharmaceutical Co., Ltd. has established itself as a key player in the healthcare sector, particularly in ophthalmology. The company's commitment to innovation is evident in its extensive pipeline, which includes several products in various stages of clinical development. Recent financial performance highlights a robust revenue growth trajectory, with the latest quarterly results demonstrating a substantial increase compared to previous periods. The strong net income margin further underscores the company's ability to maintain profitability while investing in research and development. With a solid liquidity position, Santen is well-positioned to navigate future challenges and capitalize on growth opportunities in the ophthalmic market.
AI Generated • Aug 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

3,968

CEO

Takeshi Ito

Website

www.santen.co.jp

Headquarters

Osaka, OS 530-8552, JP

SNPHF Financials

Key Financial Metrics (TTM)

Gross Margin

56.10%

Operating Margin

15.67%

Net Income Margin

13.25%

Return on Equity

13.39%

Return on Capital

13.64%

Return on Assets

9.30%

Earnings Yield

5.92%

Dividend Yield

1.90%

Payout Ratio

31.76%

Stock Overview

Market Cap

$4.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

321.19M

Volume

7

Avg. Volume

87.032

Financials (TTM)

Gross Profit

¥164.33B

Operating Income

¥45.95B

EBITDA

¥65.35B

Operating Cash Flow

¥41.22B

Capital Expenditure

-¥5.97B

Free Cash Flow

¥35.26B

Cash & ST Invst.

¥77.69B

Total Debt

¥30.78B

Santen Pharmaceutical Performance Analysis

Santen Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 2,059,878,301-13.1%
20242024-03-31JPY 2,090,975,9881.5%
20252025-03-31JPY 1,967,879,818-5.9%
20262026-03-31JPY 1,935,231,038-1.7%
Santen Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-302.0%
Q32025-12-314.0%
Q42026-03-3111.5%
Q12026-06-30-15.9%
Santen Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY -0.29N/A
20242024-03-31JPY 0.50N/A
20252025-03-31JPY 0.6835.7%
20262026-03-31JPY 0.7611.0%
Santen Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3038.9%
Q32025-12-311.5%
Q42026-03-3196.7%
Q12026-06-30-52.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥68.46B

-0.4%

Gross Profit

¥37.42B

+0.8%

Gross Margin

54.66%

N/A

Market Cap

$4.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.06M

N/A

Employees

3,968

N/A

Net Income

¥7.14B

+21.5%

EBITDA

¥12.69B

+5.1%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥77.69B

-8.1%

Total Debt

¥30.78B

+12502.8%

Accounts Receivable

¥63.15B

-6.3%

Inventory

¥64.60B

+9.0%

Long Term Debt

¥30.78B

N/A

Short Term Debt

¥0.00

N/A

Return on Assets

9.30%

N/A

Return on Invested Capital

13.54%

N/A

Free Cash Flow

¥4.27B

+10405.8%

Operating Cash Flow

¥5.22B

+9644.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BUHPFBumrungrad Hospital Public Company Limited
$5.45+0.00%
DNPUFSumitomo Pharma Co., Ltd.
$8.41+0.00%
CAMRFCamurus AB
$58.51+0.00%
CZMWYCarl Zeiss Meditec AG
$37.29+6.42%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.25+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64-0.00%
ONDSOndas
$9.16+0.03%
INTCIntel
$103.10-0.01%

Questions About SNPHF

What is the current price of Santen Pharmaceutical?

Santen Pharmaceutical is trading at $13.05 per share.

What is the 52-week range for Santen Pharmaceutical?

Over the past 52 weeks, Santen Pharmaceutical has traded between $8.88 and $13.06.

How much debt does Santen Pharmaceutical have?

As of the most recent reporting period, Santen Pharmaceutical reported total debt of ¥190.78M.

How much cash does Santen Pharmaceutical have on hand?

Santen Pharmaceutical reported ¥481.51M in cash and cash equivalents in its most recent financial results.

What is Santen Pharmaceutical’s dividend yield?

Santen Pharmaceutical currently has a dividend yield of 1.90%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services